Belite Bio
NASDAQ · BLTE·San Diego, CA·Small-cap·Phase 3
Clinical-stage biotech advancing oral small-molecule therapeutics for degenerative retinal diseases. Lead asset tinlarebant (LBS-008) is an oral RBP4 antagonist in pivotal Phase 3 trials (DRAGON for adolescent Stargardt disease, PHOENIX for geographic atrophy in dry AMD), with topline DRAGON data expected in 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Belite Bio Corporate Presentation — April 2026 | Corporate overview | April 15, 2026 | 32 |